The TCL1 locus on human chromosome 14q32.1 is activated in T-cell leukemias by translocations and inversions that juxtapose it to regulatory elements of T-cell receptor genes. We isolated and characterized four genes at this locus, TCL1 and TCL1b (T-cell leukemia/ lymphoma 1 and 1b), and TNG1 and TNG2 (TCL neighboring genes 1 and 2) all of which are overexpressed following rearrangements involving 14q32.1. TCL1 and TCL1b show 60% similarity and are represented in the mouse by a cluster of six homologous genes. In humans TCL1 and TCL1b show similar expression patterns: They are expressed mainly in CD4-/CD8-immature T-cells, pre B-cells and virgin Bcells. Expression decreases signi®cantly at more mature stages of B-cell development. Activation of TCL1 and/or TCL1b in mature T-cells causes T-cell leukemia in humans. The oncogenic nature of TCL1 was con®rmed by the analysis of a transgenic mouse model. Functional analysis of Tcl1 revealed its involvement in a PI3-kinase dependent Akt (PKB) pro-survival pathway through its interaction with the Akt kinase which increases Akt's enzymatic activity and promotes translocation of Akt to the nucleus. Oncogene (2001) 20, 5638 ± 5643.
Most human leukemias and lymphomas carry chromosomal rearrangements, predominantly translocations (Croce, 1987; Rabbitts, 1991) . These rearrangements initiate a multistep process that results in malignant transformation, although they may be also involved in tumor progression (Pegoraro et al., 1984) . The role of chromosomal translocations in the pathogenesis of human leukemias and lymphomas was ®rst demonstrated in the studies of Burkitt's lymphomas, a high grade childhood malignancy of B-cells (Dalla-Favera et al., 1982) . The rearrangements in Burkitt's lymphomas juxtapose the c-myc oncogene at 8q24 to one of the immunoglobulin loci on either 2p11, 14q32.3 or 22q11 (Ericson et al., 1982) . This results in the transcriptional activation of the c-myc oncogene by the enhancer elements of the immunoglobulin loci (arRushdi et al., 1983) . Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer developed B-cell lymphoma (Schmidt et al., 1988) . Therefore deregulation of the c-myc oncogene is the causing event in the development of Burkitt's lymphomas. Another important example for the critical role of chromosomal translocations in hematopoietic malignancies are rearrangements at involving the ALL1 gene at 11q23 (reviewed in Croce, 1999) . ALL1 can be fused to many dierent genes and even to itself in a variety of acute leukemias (Cimino et al., 1991; Gu et al., 1992; Schichman et al., 1994) . The critical role of ALL1 in the pathogenesis of ALL was con®rmed by the study of ALL1 transgenic mouse models showing the development of acute leukemias (Corral et al., 1996) . Since ALL1 has so many dierent fusion partners it is likely that the oncogenic event in this rearrangement is the loss of function of this gene.
Chromosomal rearrangements and genes at 14q32.1
Rearrangements at the TCL1 (T-cell leukemia/lymphoma 1) locus are associated with T-cell leukemias of the mature phenotype such as T-cell prolymphocytic leukemia (T-PLL) , adult T-cell leukemia (ATL) (Narducci et al., 1997) and with chronic T-cell leukemias that develop in patients with the immunode®ciency syndrome ataxia telangiectasia (AT) (Brito-Babapulle and Catovsky, 1991) . Most often, the TCL1 locus at chromosome 14q32.1 rearranges with the TCR (T-cell receptor) a/d locus at chromosome 14q11 (Figure 1) (Russo et al., 1989; Virgilio et al., 1993) . Since both loci reside on the same chromosome, these rearrangements can either be reciprocal translocations t(14;14)(q11;q32) or inversions inv(14)(q11;q32). In the case of the translocation t(14;14)(q11;q32) the abnormal chromosome 14 contains two copies of the TCL1 locus: one normal copy in the distal part of the chromosome and one rearranged TCL1 copy juxtaposed to the J segment of the TCRa/d receptor (Figure 1 ). On the chromosome 14 carrying the inversion inv(14)(q11;q32) the rearranged TCL1 locus is also linked to a J/D segment of the TCRa receptor, although in this case the orientation of the TCL1 locus is opposite to that of the translocation t(14;14)(q11;q32) ( Figure 1 ). The activation of TCL1 by both types of rearrangements suggests that the TCRa enhancer may activate the locus either in 3' or in 5' orientation. It is also important to note, that rearrangements of the TCL1 locus have been observed in T-cell clonal expansions occurring in patients with AT before the onset of frank leukemia (Narducci et al., 1995) .
Since the TCL1 locus at 14q32.1 is frequently involved in chromosomal rearrangements in T-cell leukemias we speculated that an oncogene important for the induction and/or development of T-cell leukemias is located in this region (Croce et al., 1985) . To isolate this gene(s) we ®rst constructed a P1 contig covering 14q32.1 and mapped several 14q32.1 breakpoints within this region (Virgilio et al., 1993) . Genomic analysis of our contig revealed that an approximately 120 kb DNA segment is located between two clusters of breakpoints observed in various leukemic samples and cell lines (Figure 2 ). Further analysis of this 120 kb region resulted in the discovery of the TCL1 gene formed by four exons with a coding sequence of 114 amino acids and a 3' untranslated region of about 800 nucleotides (Virgilio et al., 1994, Figure 2 ). The Tcl1 protein shares a 41% amino acid sequence identity with the peptide encoded by one of the open reading frames of the MTCP1 gene located at Xq28 and activated in rare cases of mature T-cell leukemia with a t(X;14)(q28;q11) translocation (Stern et al., 1993; Madani et al., 1996) .
Additional studies have shown that TCL1 becomes activated as a consequence of the TCL1 locus rearrangements and that its activation is the ®rst step in T-cell neoplasia (Virgilio et al., 1994 (Virgilio et al., , 1998 . However, some cases of T-cell malignancies with abnormalities, such as gene ampli®cation at 14q32.1, did not show activation of TCL1 expression (Ariyama et al., 1999; Sakashita et al., 1998; Takizawa et al., 1998) , suggesting that perhaps an additional oncogene may be located in 14q32.1 (Takizawa et al., 1998) . In order to look for this putative additional oncogene we further analysed the 14q32.1 breakpoint region and found three additional genes: TNG1 (TCL1 neighboring gene 1), TNG2 and TCL1b Pekarsky et al., 1999) . Expression analysis of these genes showed a complex alternative splicing pattern including fusion transcripts between the genes. TNG1 and TNG2 encode proteins with no signi®cant homology to any known proteins or protein motifs . TCL1b is located only 15 kb centromeric of TCL1 with the opposite direction of transcription ( Figure 2 ). Interestingly TCL1b, encodes a 14 kD protein of 128 amino acids, which shows 60% similarity to TCL1, and contains an insertion of 14 amino acids when compared to TCL1 .
To develop mouse models for the 14q32.1 oncogenic locus we also characterized the murine counterpart of that region. EST analysis of murine Tcl1 and Tcl1b orthologs suggested the existence of several Tcl1b genes in the mouse. Sequence analysis of a BAC clone containing the murine Tcl1 locus revealed the existence of ®ve dierent Tcl1b homologs adjacent to the murine Tcl1 gene . All six genes span an 80 kb DNA segment on the murine chromosome 12 (Figure 3 ). Expression analysis revealed mRNA for all ®ve Tcl1b genes (Tcl1b1 ± Tcl1b5) encoding similar but distinct proteins .
Expression analysis of the TCL1 locus in normal tissues and hematopoietic malignancies
To determine the relevance of all the genes at the TCL1 locus in T-cell leukemogenesis we proceeded to investigate the expression analysis of these genes. Since its discovery, the expression of TCL1 in normal and tumor tissues has been studied in great detail. The protein can be found in most stages of B-cell development including pre-B-cells, surface lgM expres- (Narducci et al., 2000; Takizawa et al., 1998) . It is down regulated only at later stages of B-cell development, i.e. plasma cells. In T-cells, however, TCL1 is only expressed at the very early CD47/CD87 double negative stage (Virgilio et al., 1994; Narducci et al., 2000) . More mature T-cells do not normally show any TCL1 expression (Figure 4 ). Other non-lymphatic tissues or cell lines tested also do not express TCL1 with the exception of ovaries and ovarian tumors (Virgilio et al., 1994) . In contrast to this normal expression pattern, we showed that the TCL1 oncogene is activated by chromosomal translocations in the majority of T-PLLs (Virgilio et al., 1994) and leukemias arising in patients with ataxia telangiectasia (AT) . TCL1 is also overexpressed in adult T-cell leukemias (ATL) when compared to normal T-cells (Narducci et al., 1997) . Consistent with this ®nding TCL1, is also activated in the SupT11 leukemic T-cell line, that carries a t(14 : 14)(q11;q32) chromosomal translocation (Virgilio et al., 1994, Figure 4) . Some of the breakpoints that are seen in these types of leukemias are shown in Figure 2 . The other three genes in this locus, TCL1b, TNG1 and TNG2, show an expression pattern very similar to that of TCL1. Most importantly, they are not expressed in most normal T-cells, but activated in the SupT11 cell line and in samples from T-PLL patients as shown in Figure 3 .
Interestingly, the expression pattern of the genes of the murine Tcl1 locus is signi®cantly dierent. Expression of murine Tcl1 and Tcl1b genes was not detected in any of the adult mouse tissues analysed, including lymphoid tissues, although a detailed study of the expression in murine lymphogenesis is yet to be carried out. The only signi®cant expression of these genes was found in oocytes and at the earliest stages of mouse embryogenesis .
TCL1 is a bona fide oncogene
Activation of TCL1 in T-cell leukemia can be explained through two dierent mechanisms: TCL1 expression is causative in T-cell leukemia or it is a nonessential secondary event. To prove that TCL1 is a bona ®de oncogene involved in tumor initiation we introduced the human TCL1 cDNA under the control of the lck proximal promoter into fertilized mouse eggs (Virgilio et al., 1998) . These transgenic mice developed premalignant T-cell proliferations expressing TCL1 cDNA starting at the age of 6 months. Older mice (in average 15 month of age) developed mature T-cell leukemias. Interestingly, the leukemias in the transgenic mice were predominatly CD47/CD8+ in contrast to human leukemias with TCL1 involvement which are mostly CD4+/CD87 (Virgilio et al., 1998) . With the aid of this mouse model we were able to prove that TCL1 is an actual oncogene and that its deregulation initiates the process of malignant transformation. The introduction of another member of the TCL1 gene family, MTCP1, under the control of the CD2 promoter (another T-cell speci®c promoter) resulted in the development of a similar type of leukemia in that transgenic model, although with a CD47/CD8+ phenotype (Gritti et al., 1998) . Thus, deregulation of two members of the TCL1 gene family, TCL1 and MTCP1, in T-cells causes the development of T-cell leukemias in transgenic animals at older ages similar to adult T-cell leukemias in humans. It will be of considerable interest to determine whether TCL1b transgenic mice also develop mature T-cell leukemia late in life and whether TCL1 and TCL1b may synergize to lead to an earlier onset of the disease.
Functional aspects of Tcl1
Although several reports demonstrated the involvement of TCL1 in the pathogenesis of T-cell leukemias and that the activation of the gene is the causing event in the development of human T-cell malignancies, the way in which Tcl1 acts to achieve its oncogenic eect was not known until recently. To identify the molecular role of Tcl1 and interacting proteins we looked at other proteins involved in T-cell leukemogenesis. Among the proteins we considered for investigation was the protein kinase Akt/PKB. Akt is the human homolog of v-akt, a gene isolated from the retrovirus AKT8, which causes T-cell lymphomas in mice (Staal et al., 1977) . Akt is a key player in the transduction of anti-apoptotic and proliferative signals in T-cells (reviewed in Chan et al., 1999) . Recent studies have shown that Akt phosphorylates and regulates a variety of key targets important for cell survival and proliferation like Bad (Mok et al., 1999) , Raf (Zimmermann and Moelling, 1999) , and IKKa (Ozes et al., 1999) . Introduction of a constitutively activated Akt under the control of the proximal lck promoter causes T-cell lymphomas in mice. Akt contains a pleckstrin homology domain which is thought to mediate protein ± protein interactions, and a kinase domain. The protein kinase can be activated by insulin and various other growth and survival factors (reviewed in Chan et al., 1999) .
To explore the possibility that Tcl1 and Akt function in the same pathway, we ®rst investigated whether the two proteins interact physically. Co-immunoprecipitation experiments demonstrated that Akt1 forms immune complexes with Tcl1. Investigation of the other members of the two gene families (Tcl1b, Akt2, and Akt3) showed no signi®cant interaction between either of them as determined by immunoprecipitation (Pekarsky et al., 2000) . Another study has demonstrated co-immunoprecipitation of Akt1 and Mtcp1 and interaction of Akt2 and Tcl1, Tcl1b, and Mtcp1 in the more sensitive yeast two hybrid system (Laine et al., 2000) . Studies of the eect of Tcl1 on Akt function found that Tcl1 enhances the kinase activity of Akt (Pekarsky et al., 2000; Laine et al., 2000) . The activation of Akt by growth and survival factors involves a phosphatidylinositol 3-kinase (PI3-K)-dependent membrane translocation step that is attributed to the binding of the PH-domain to D3 phosphoinositides and a PDK-1 mediated phosphorylation step of Trp308 and Ser473 (Chan et al., 1999) . A recent report showed that Tcl1 promotes the oligomerization of Akt and thereby enhances its kinase activity (Laine et al., 2000) . The same study also claimed that Tcl1 enhances the phosphorylation of Ser473 of Akt, although our results could not con®rm this ®nding. Therefore we believe that the interaction of Tcl1 and Akt1 causes a conformational change of Akt by oligomerization or interaction with other proteins which increases the kinase activity of Akt.
The intracellular localization of Akt is primarily cytoplasmic (Chan et al., 1999) . Tcl1, on the other hand, is located in both the cytoplasm and the nucleus (Pekarsky et al., 2000) . Our two color immuno¯uores-cence experiments showed that co-expression of Akt1 and Tcl1 in the same cells leads to co-localization of both proteins in the nucleus and the cytoplasm. Coexpression of myristoylated Akt (con®ned to the cytoplasm) and Tcl1 con®rmed this co-localization by retaining Tcl1 in the cytoplasm (Pekarsky et al., 2000) . Thus, we and others demonstrated that Tcl1 interacts with Akt1, enhances Akt1 kinase activity and promotes the nuclear translocation of Akt1. The enzymatic activity of Akt is critical for its oncogenic function (i.e. for phosphorylation and regulation of cell cycle regulatory molecules such as Bad, Raf, and IKKa), therefore the enhancement of this activity by Tcl1 represents one mechanism of Tcl1 oncogenic function. Since all reported targets of Akt are cytoplasmic our ®nding that Tcl1 translocates Akt to the nucleus led us to believe that there is at least one nuclear target of Akt that is important for T-cell proliferation or death.
Our results led us to search for such a T-cell speci®c nuclear target containing an Akt phosphorylation site. The orphan nuclear receptor Nur77 (also known as NGFI-B or TR3) drew our attention: Nur77 is a critical molecule for apoptosis in T-cells and it has an Akt phosphorylation site at Ser350 (Cheng et al., 1997) . It is required for T-cell antigen receptor mediated apoptosis in immature thymocytes undergoing selection and it is induced in T-cell hybridomas (Cheng et al., 1997) . The transactivational activity of Nur77 is mediated through a unique response element (Davis et al., 1993) . The phosphorylation of Ser350, located in the DNA-binding domain, was shown to inhibit the DNA binding and transcriptional activity of Nur77 in vitro (Hirata et al., 1993) and in vivo (Katagiri et al., 1997) . Our experiments showed that Akt interacts with and phosphorylates Nur77 at Ser350 in a PI3-K dependent manner and thereby inhibits the function of Nur77 as a proapoptotic transcription factor. Cell fractionation experiments revealed that phosphorylation of Nur77 by Akt took place in the cytoplasm and that the rate of phosphorylation was not in¯uenced by the presence of Tcl1 (Pekarsky et al., 2001) indicating that Tcl1 levels do not aect Nur77 activity. Nevertheless it is premature to conclude that Tcl1 is not involved in the regulation of Nur77 since we conducted our experiments in an overexpressed system in non-lymphoid cells.
Conclusions
The analysis of chromosomal translocations in human T-cell malignancies resulted in the identi®cation of a family of genes that are important for the development, dierentiation, proliferation and apoptosis of hematopoietic cells. Activation of TCL1, one of the members of this family, is a crucial initial step in the development of T-cell leukemias, as was proven in the transgenic mouse model (Virgilio et al., 1998) . Nevertheless, other genetic changes are probably necessary for the pathogenesis of a full-blown leukemia, since the mice develop a mature T-cell leukemia late in life (Virgilio et al., 1998) .
On the other hand, TCL1 is not the only gene that can be activated by chromosomal aberrations involving 14q32.1. TCL1b, TNG1, and TNG2 may also be involved in the pathogenesis of T-cell malignancies, and may be acting as oncogenes on their own or in concert with TCL1 or each other Pekarsky et al., 1999) . Although the exact biological function of Tcl1 is still not clear, we were able to demonstrate its involvement in the enhancement of the PI3-K dependent anti-apoptotic function of Akt (Pekarsky et al., 2000) . Tcl1 also transports Akt to the nucleus. However, because Tcl1 has no nuclear localization signal, the exact mechanism of this phenomenon needs to be studied. The nuclear translocation of Akt by Tcl1 hints to the existence of nuclear target(s) of Akt important for the survival and/ or apoptosis of T-cells. Additional experiments are necessary to identify these target(s), since Nur77 turned out to be phosphorylated by Akt in the cytoplasm (Pekarsky et al., 2001) .
The complete understanding of the molecular mechanisms utilized by the members of the TCL1 oncogene family will provide invaluable tools toward the understanding of the molecular bases of T-cell leukemia molecular bases and will lead to development of novel targeted therapeutic approaches to this disease and other tumors as well.
